Tag Archive for: bispecific antibody

Merus headquarters in Utrecht, The NetherlandsMerus NV
M&A

Genmab swallows Merus in US$8bn deal

Danish Genmab A/S has acquired the Dutch oncology specialist Merus NV for US$8bn in cash. The 41% premium over Merus’s share price at Friday is largely attributed to the bispecific EGFR x LGR5 antibody, Petosemtamab

Read more
DrenBioDren Bio Inc
Licence deal

Sanofi to acquire Dren Bio’s bispecific myeloid cell engager DR-201

French Sanofi SA announced that it will acquire Dren Bio Inc’s bispecific myeloid cell engager DR-0201 for upfront US$600m and US$1.3bn in milestones. The deal is expected to close in Q2/2025.

Read more